AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 JAN 21 - (NewsRx.com & NewsRx.net) -- Researchers have published a cost-utility analysis of different vaccine strategies for invasive meningococcal and pneumococcal disease in Switzerland in a recent issue of the journal Vaccine.
"We performed a cost-utility analysis for various vaccination strategies against meningococcal and pneumococcal diseases (MenC or MenC/PCV-9) in Switzerland. The analysis compared the current recommendations of vaccinating only children with medical risks to the introduction of the vaccination with either the MenC or the MenC/PCV-9 vaccine, administered at 12 or 2, 4, and 6 months of age, into the existing immunization program," researchers in Switzerland report.
"For a birth cohort of 80,000 children and assuming a vaccine coverage of 80%, the introduction of a generalized vaccination would be cost-effective," said Helene Jaccard Ruedin and collaborators at the Swiss Federal Office of Public Health in Bern and Hirslanden Research in Zurich. "The strategy using three doses of ...
Source: HighBeam Research, Cost-utility analysis of vaccine strategies in Switzerland released.